Sign In
Buy AGEN
$3.07
+0.0300 (+0.99%)
At Close: Jun 23, 2026
Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves
12:08pm, Tuesday, 16'th Jun 2026
Agenus NASDAQ: AGEN told shareholders at its 2026 virtual annual meeting that it remains focused on advancing its botensilimab and balstilimab immunotherapy combination, known as BOT/BAL, while workin
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?
12:31pm, Wednesday, 10'th Jun 2026
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock?
AGEN Early Access Revenues Signal a New Path Ahead of Approval
03:05pm, Friday, 05'th Jun 2026
Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.
Is Agenus Stock a Hold Amid Valuation and Funding Risks?
03:02pm, Friday, 05'th Jun 2026
AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, dilution risk and a going-concern warning.
AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC
02:55pm, Friday, 05'th Jun 2026
Agenus bets on BOT+BAL in MSS mCRC, and the phase III BATTMAN trial determines whether early survival signals translate into a pivotal win.
Agenus Announces Virtual 2026 Annual Shareholders Meeting
04:30pm, Tuesday, 02'nd Jun 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at
AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?
11:50am, Thursday, 28'th May 2026
Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.
How Agenus' Pipeline Progress Unlock Its Next Growth Phase
01:35pm, Tuesday, 26'th May 2026
AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.
Agenus: Weighing The Clinical Progress Against The Company's Cash
07:25am, Tuesday, 26'th May 2026
Agenus: Weighing The Clinical Progress Against The Company's Cash
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AI--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new retrospective data showing that Noetik's artificial intelligenc
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #ASCO2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the first disclosure of Phase 2 data from the C-800-23 study
AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell?
02:21pm, Thursday, 21'st May 2026
Agenus' shares slide after weak Q1 results, but BOT/BAL phase III progress, survival data and Zydus backing keep long-term growth hopes alive.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of Phase 1b data evaluating botensilimab (BOT), a
Agenus (AGEN) Q1 Earnings and Revenues Miss Estimates
09:06pm, Monday, 11'th May 2026
Agenus (AGEN) came out with quarterly earnings of $1.02 per share, missing the Zacks Consensus Estimate of $2.1 per share. This compares to a loss of $1.03 per share a year ago.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BATTMAN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the first quarter ended March 31, 2026, a
